AI Article Synopsis
- Since its isolation in 1957, rifamycin B has been extensively researched, improving our knowledge of its taxonomy, genetics, and production processes.
- Key advancements have been made in genetic tools, especially through Heinz Floss's work on cloning vectors and the rifamycin biosynthetic gene cluster, enabling the creation of rifamycin B analogues that could combat multi-drug-resistant tuberculosis.
- New genomic technologies, like CRISPR, may help enhance the production of these analogues, addressing previous limitations in their yield.
Article Abstract
Ever since the isolation of in 1957, this strain has been the focus of research worldwide. In the last 60 years or more, our understanding of the taxonomy, development of cloning vectors and conjugation system, physiology, genetics, genomics, and biosynthetic pathway of rifamycin B production in . has substantially increased. In particular, the development of cloning vectors, transformation system, characterization of the rifamycin biosynthetic gene cluster, and the regulation of rifamycin B production by the pioneering work of Heinz Floss have made the rifamycin polyketide biosynthetic gene cluster (PKS) an attractive target for extensive genetic manipulations to produce rifamycin B analogues which could be effective against multi-drug-resistant tuberculosis. Additionally, a better understanding of the regulation of rifamycin B production and the application of newer genomics tools, including CRISPR-assisted genome editing systems, might prove useful to overcome the limitations associated with low production of rifamycin analogues.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jnatprod.3c00686 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!